Search results for "Fresh frozen"

showing 9 items of 19 documents

Intramedullary nailing vs. palmar locked plating for unstable dorsally comminuted distal radius fractures: A biomechanical study

2010

Abstract Background The purpose of this study was to compare the stability of a 2.4 mm palmar locking compression plate and a new intramedullary nail-plate-hybrid Targon DR for dorsally comminuted distal radius fractures. Methods An extraarticular 10 mm dorsally open wedge osteotomy was created in 8 pairs of fresh frozen human radii to simulate an AO–A3-fracture. The fractures were stabilized using one of the fixation methods. The specimens were loaded axially with 200 N and dorsal-excentrically with 80 N. 2000 cycles of dynamic loading and axial loading-to-failure were performed. Findings Axial loading revealed that intramedullary osteosynthesis (Targon DR: 369 N/mm) was significantly ( p …

Orthodonticsmedicine.medical_specialtyMaterials scienceOsteosynthesisBiophysicsRadiusLocked platingIn Vitro TechniquesCompression (physics)Biomechanical PhenomenaFracture Fixation Intramedullarylaw.inventionSurgeryIntramedullary rodFracture Fixation InternalFixation (surgical)lawLoad to failureFresh frozenmedicineHumansOrthopedics and Sports MedicineRadius FracturesBone PlatesFractures ComminutedClinical Biomechanics
researchProduct

Adverse Events in Treatment of Inherited Factor VII Deficiency: Final Analysis of the STER

2012

Abstract Abstract 2279 Introduction No evidence-based guidelines are available for the treatment of Factor VII deficiency. Replacement therapy (RT) is still influenced by different factors as rarity of the disorder, availability and supply of products and economic reasons. All RTs are not exempt of side effects and scanty data is available about the safety of the products currently used. Aim of this study was to analyze adverse events (AEs) of RTs for congenital Factor VII deficiency, as reported in Seven Treatment Evaluation Registry (STER). Design and Methods FVII deficiency patients treated for bleeding episodes, prophylaxis, and surgery were investigated for RT-related AEs over a period…

Pediatricsmedicine.medical_specialtySuperficial vein thrombosisFactor VIIbusiness.industryImmunologyAdverse Events Inherited Fasctor VII deficiencyCell BiologyHematologymedicine.diseaseBiochemistryThrombosisProthrombin complex concentratechemistry.chemical_compoundchemistryMedicineObservational studyFresh frozen plasmabusinessFactor VII deficiencyAdverse effectmedicine.drug
researchProduct

Evolving Risk Factors for Mortality after Lung Transplantation over the Last 10 Years: Insights from a Single-Centre Database

2016

s S233 218 (82%) patients received pooled platelet transfusion -median (IQR) 1(1-2) U. 209 (79%) and 129 (49%) patients received fresh frozen plasma (FFP) and cryoprecipitate with a median (IQR) of 3(2-4) and 0(0-0) U respectively. Conclusion: Rate and volume of transfusion of blood products compare favourably with centres performing surgery off CPB or on ECMO. Requirement for ECMO particularly for BTT, but also PGD is associated with high transfusion requirements.

Pulmonary and Respiratory MedicineTransplantationmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentSurgerySingle centresurgical procedures operativePlatelet transfusionCryoprecipitatemedicineLung transplantationSurgeryFresh frozen plasmaCardiology and Cardiovascular MedicinebusinessIntensive care medicineThe Journal of Heart and Lung Transplantation
researchProduct

Blood Component Therapy and Coagulopathy in Trauma: A Systematic Review of the Literature from the Trauma Update Group

2016

Background Traumatic coagulopathy is thought to increase mortality and its treatment to reduce preventable deaths. However, there is still uncertainty in this field, and available literature results may have been overestimated. Methods We searched the MEDLINE database using the PubMed platform. We formulated four queries investigating the prognostic weight of traumatic coagulopathy defined according to conventional laboratory testing, and the effectiveness in reducing mortality of three different treatments aimed at contrasting coagulopathy (high fresh frozen plasma/packed red blood cells ratios, fibrinogen, and tranexamic acid administration). Randomized controlled trials were selected alo…

Tranexamic acidPhysiologyGlycobiologylcsh:MedicineCardiovascular MedicinePathology and Laboratory MedicineBiochemistryVascular Medicinelaw.inventionDatabase and Informatics MethodsFresh frozen plasma0302 clinical medicineRandomized controlled trialCoagulopathyAnimal CellslawAntifibrinolytic agentFibrinogen; Fresh frozen plasma; Tranexamic acid; Antifibrinolytic agent.Medicine and Health Sciences030212 general & internal medicineDatabase Searchinglcsh:ScienceMultidisciplinaryPlasma ExchangeHematologyBlood Coagulation DisordersClinical Laboratory SciencesAntifibrinolytic AgentsBody FluidsBloodtraumaTranexamic AcidCardiovascular DiseasesResearch DesignMeta-analysisObservational StudiesFresh frozen plasmaAnatomyCellular TypesResearch ArticlePlateletsmedicine.medical_specialtyDeath RatesHemorrhageBlood Component TransfusionResearch and Analysis MethodsExternal validity03 medical and health sciencesSigns and SymptomsPopulation MetricsDiagnostic MedicinemedicineCoagulopathyHumansBlood TransfusionMortalityIntensive care medicineBlood CoagulationAntifibrinolytic Agents; Blood Coagulation Disorders; Humans; Mortality; Plasma Exchange; Tranexamic Acid; Wounds and Injuries; Blood Component Transfusion; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)DemographyGlycoproteinsBlood CellsAntifibrinolytic agentPopulation BiologyCoagulation DisordersTransfusion Medicinebusiness.industrylcsh:RBleedingAntifibrinolytic agent.Biology and Life SciencesFibrinogen030208 emergency & critical care medicineCell Biologymedicine.diseaseSurgeryPeople and PlacesWounds and Injurieslcsh:QObservational studyPacked red blood cellsbusinessPLOS ONE
researchProduct

Tranexamic acid in cardiac surgery: Are low doses enough?

2020

OBJECTIVES Tranexamic acid is used to prevent hyperfibrinolysis and reduce postoperative bleeding and blood transfusions in on-pump cardiac surgery. We evaluate the efficacy of low or high dose tranexamic acid in a prospective cohort study conducted in Valencia. MATERIALS AND METHODS A total of 427 patients were recruited between January 2019 and January 2020, 207 in the Hospital General Universitario (low dose [LD]) and 220 in the Hospital Universitario y Politecnico La Fe (high dose [HD] and intermediate dose [ID]). We recorded the presence of hyperfibrinolysis on rotational thromboelastometry, intra- and postoperative administration of blood products, chest tube output within the first 1…

Univariate analysismedicine.medical_specialtybusiness.industrymedicine.medical_treatmentGeneral MedicinePostoperative Hemorrhagemedicine.diseaseHyperfibrinolysisAntifibrinolytic AgentsCardiac surgeryThromboelastometryTranexamic AcidAnesthesiaFibrinolysismedicineHumansFresh frozen plasmaProspective StudiesCardiac Surgical ProceduresbusinessProspective cohort studyTranexamic acidmedicine.drugRevista espanola de anestesiologia y reanimacion
researchProduct

Management of the Sponataneous Bleeding Episodes in Factor VII Deficiency. A Prospective Evaluation of the STER,

2011

Abstract Abstract 3368 Introduction Patients with an inherited factor VII (FVII) deficiency may display a wide range of clinical phenotypes, from an asymptomatic condition to serious hemorrhagic episodes such as fatal central nervous system (CNS) or gastrointestinal (GI) bleeds (Mariani G et al. Thromb Haemost 2005; 93: 481–7). Symptomatic patients can be divided into two major categories: those with mild-to-moderate bleeding tendency and individuals with a severe bleeding tendency which may be more severe than that in hemophilia. The former group mainly experience mucosal bleeding, a clinical picture that mimics that of a platelet disorder and often does not call for treatment. In contrast…

medicine.medical_specialtyFactor VIIbusiness.industryPlatelet disorderImmunologyCell BiologyHematologyBleedmedicine.diseaseHaemophiliaBiochemistryAsymptomaticGastroenterologySurgerychemistry.chemical_compoundHematomaHemophiliaschemistryInternal medicinemedicineFresh frozen plasmamedicine.symptombusinessBlood
researchProduct

Pediatric non-red cell blood product transfusion practices: what's the evidence to guide transfusion of the ‘yellow’ blood products?

2020

Purpose of review Research studies pertaining to the management of pediatric non-red cell blood product transfusion is limited. Clinical practices vary within disciplines and regions. Anesthesiologists need evidence-based guidelines to make appropriate and safe decisions regarding transfusion of the 'yellow' blood products for pediatric patients. Recent findings This review outlines clinical indications for transfusion of fresh frozen plasma, cryoprecipitate, platelets, and fibrinogen concentrate in pediatrics. Recent studies of non-red blood cell transfusions in critical, but stable situations are highlighted. Recommendations to guide transfusion of the 'yellow' blood products in operative…

medicine.medical_specialtyRed Cellbusiness.industryMEDLINE030204 cardiovascular system & hematologyFibrinogenBlood cell03 medical and health sciences0302 clinical medicineAnesthesiology and Pain Medicinemedicine.anatomical_structureBlood productCryoprecipitatemedicinePlatelet030212 general & internal medicineFresh frozen plasmaIntensive care medicinebusinessmedicine.drugCurrent Opinion in Anaesthesiology
researchProduct

Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management

2021

Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and ischemic end organ injury due to microvascular platelet-rich thrombi. TTP results from a severe deficiency of the specific von Willebrand factor (VWF)-cleaving protease, ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13). ADAMTS13 deficiency is most commonly acquired due to anti-ADAMTS13 autoantibodies. It can also be inherited in the congenital form as a result of biallelic mutations in the ADAMTS13 gene. In adults, the condition is most often immune-mediated (iTTP) whereas congenital TTP (cTT…

medicine.medical_specialtyThrombotic microangiopathyTTPdiagnosisThrombotic thrombocytopenic purpuralcsh:MedicineReview030204 cardiovascular system & hematologycaplacizumabGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorhemic and lymphatic diseasesInternal medicinefollow-upmedicinethrombotic thrombocytopenic purpuratreatmentbiologybusiness.industrylcsh:RGeneral MedicineMicroangiopathic hemolytic anemiamedicine.diseaseADAMTS13ADAMTS13biology.proteinRituximabFresh frozen plasmaCaplacizumabbusiness030215 immunologymedicine.drugJournal of Clinical Medicine
researchProduct

Bleeding in Uremia

2021

Progressive deterioration of renal function eventually leads to uremia, which is associated with impaired function of platelets and a disturbed platelet–vessel wall interaction thus increasing the risk of bleeding in patients with renal failure. Furthermore, also anemia and anticoagulants/antiplatelet drugs contribute to the increased risk of bleeding in patients with end stage renal disease. Management of bleeding episodes in uremic patients includes an adequate dialysis, the correction of anemia with erythropoietin or erythropoetin stimulating agents, the administration of estrogens, desmopressin, fresh frozen plasma, cryoprecipitate, factor VIIa, or tranexamic acid. In severe bleeding ep…

medicine.medical_specialtybusiness.industryAnemiamedicine.medical_treatmentmedicine.diseaseGastroenterologyUremiaEnd stage renal diseaseCryoprecipitateInternal medicineMedicineFresh frozen plasmabusinessDesmopressinDialysisTranexamic acidmedicine.drug
researchProduct